---
title: "BridgeBioâ€™s receives EU approval for its Transthyretin Amyloidosis treatment"
date: "2025-02-11 18:58:35"
summary: "BridgeBio Pharma (NASDAQ:BBIO) announced that the European Commission has granted marketing authorization for acoramidis, sold under the brand name BEYONTTRA, in the European Union. It is approved for treating adult patients with wild-type or variant transthyretin amyloidosis with cardiomyopathy. The EU approval is based on the results of the pivotal..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482562791/image_1482562791.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* BridgeBio Pharma (NASDAQ:[BBIO](https://seekingalpha.com/symbol/BBIO "BridgeBio Pharma, Inc.")) announced that the European Commission has granted marketing authorization for acoramidis, sold under the brand name BEYONTTRA, in the European Union.
* It is approved for treating adult patients with wild-type or variant transthyretin amyloidosis with cardiomyopathy.
* The EU approval is based on the results of the pivotal ATTRibute-CM Phase 3 study, which demonstrated significant benefits for cardiovascular outcomes.
* Following this approval, Bayer plans to launch acoramidis in the first half of 2025.
* The drug is also under review by the Japanese Pharmaceuticals and Medical Devices Agency and the Brazilian Health Regulatory Agency.
* Source: [Press Release](https://seekingalpha.com/pr/19998469-beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-percent-approved-by-the)

[seekalpha](https://seekingalpha.com/news/4406187-bridgebios-receives-eu-approval-for-its-transthyretin-amyloidosis-treatment)
